About Elite™ Hemagglutinin (H3N2) (A/Brisbane/10/2007) ELISA Kit

Influenza A (H3N2) viruses are among the most clinically significant seasonal influenza viruses, causing substantial morbidity and mortality worldwide. The viral hemagglutinin (HA) glycoprotein is the major surface antigen responsible for binding sialic acid receptors on host epithelial cells, initiating viral entry, and eliciting protective neutralizing antibody responses. Because HA is the primary antigen incorporated into influenza vaccines and the principal target of antiviral antibodies, accurate quantification of recombinant HA is essential for vaccine development, antigen production, virology research, and quality control. The A/Brisbane/10/2007 (H3N2) strain was recommended by the WHO and FDA as a vaccine strain for the 2008–2009 and 2009–2010 Northern Hemisphere influenza seasons, making it an important reference strain for influenza research.

The Elite™ Hemagglutinin (H3N2) (A/Brisbane/10/2007) ELISA Kit is a highly sensitive streptavidin/biotin-based sandwich ELISA developed for the quantitative determination of Influenza A H3N2 hemagglutinin (HA) in cell culture supernatants and serum samples. The assay provides a quantitative detection range of 0.5–32 ng/mL, delivering excellent sensitivity, specificity, and reproducibility for monitoring recombinant HA expression and vaccine antigen production. Supplied in a 96-well microplate format, the assay is read at 450 nm using a standard ELISA microplate reader and is suitable for routine laboratory analysis, process development, and high-throughput sample testing.

Applications

Biological Significance of Influenza A H3N2 Hemagglutinin

Hemagglutinin is the major envelope glycoprotein of influenza A viruses and mediates the first step of viral infection by recognizing α2,6- and α2,3-linked sialic acid receptors, followed by receptor-mediated endocytosis and low-pH-induced membrane fusion. HA is also the dominant antigen recognized by the host immune system and the principal target of neutralizing antibodies generated by natural infection or vaccination. Continuous antigenic drift within the H3 hemagglutinin protein drives the emergence of new seasonal influenza variants, requiring frequent updates of vaccine formulations. Quantitative measurement of H3N2 HA is therefore essential for recombinant antigen production, vaccine potency evaluation, antigen characterization, immune response studies, and antiviral therapeutic development. The Elite™ Hemagglutinin (H3N2) (A/Brisbane/10/2007) ELISA Kit provides a reliable, sensitive, and reproducible platform for influenza virology, immunology, vaccine research, and biopharmaceutical manufacturing.